135 related articles for article (PubMed ID: 14422)
1. Absorption, metabolism and excretion of safrole in the rat and man.
Benedetti MS; Malnoë A; Broillet AL
Toxicology; 1977 Feb; 7(1):69-83. PubMed ID: 14422
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the biliary and urinary glutathione and N-acetylcysteine metabolites of the hepatic carcinogen 1'-hydroxysafrole and its 1'-oxo metabolite in rats and mice.
Fennell TR; Miller JA; Miller EC
Cancer Res; 1984 Aug; 44(8):3231-40. PubMed ID: 6744260
[TBL] [Abstract][Full Text] [Related]
3. The metabolic sulfonation and side-chain oxidation of 3'-hydroxyisosafrole in the mouse and its inactivity as a hepatocarcinogen relative to 1'-hydroxysafrole.
Boberg EW; Miller EC; Miller JA
Chem Biol Interact; 1986; 59(1):73-97. PubMed ID: 3757147
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of the proximate carcinogen 1'-hydroxysafrole and the isomer 3'-hydroxyisosafrole.
Peele JD; Oswald EO
Bull Environ Contam Toxicol; 1978 Apr; 19(4):396-402. PubMed ID: 656641
[No Abstract] [Full Text] [Related]
5. Metabolism of isosafrole and dihydrosafrole in the rat.
Klungsøyr J; Scheline RR
Biomed Mass Spectrom; 1982 Aug; 9(8):323-9. PubMed ID: 7126764
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of safrole in the rat.
Klungsøyr J; Scheline RR
Acta Pharmacol Toxicol (Copenh); 1983 Mar; 52(3):211-6. PubMed ID: 6846029
[TBL] [Abstract][Full Text] [Related]
7. The metabolic activation of the carcinogen 1'-hydroxysafrole in vivo and in vitro and the electrophilic reactivities of possible ultimate carcinogens.
Wislocki PG; Borchert P; Miller JA; Miller EC
Cancer Res; 1976 May; 36(5):1686-95. PubMed ID: 5188
[TBL] [Abstract][Full Text] [Related]
8. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice.
Randerath K; Haglund RE; Phillips DH; Reddy MV
Carcinogenesis; 1984 Dec; 5(12):1613-22. PubMed ID: 6499112
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole.
Miller EC; Swanson AB; Phillips DH; Fletcher TL; Liem A; Miller JA
Cancer Res; 1983 Mar; 43(3):1124-34. PubMed ID: 6825084
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based biokinetic (PBBK) model for safrole bioactivation and detoxification in rats.
Martati E; Boersma MG; Spenkelink A; Khadka DB; Punt A; Vervoort J; van Bladeren PJ; Rietjens IM
Chem Res Toxicol; 2011 Jun; 24(6):818-34. PubMed ID: 21446753
[TBL] [Abstract][Full Text] [Related]
11. Strong evidence from studies with brachymorphic mice and pentachlorophenol that 1'-sulfoöxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1'-hydroxysafrole in mouse liver.
Boberg EW; Miller EC; Miller JA; Poland A; Liem A
Cancer Res; 1983 Nov; 43(11):5163-73. PubMed ID: 6577945
[TBL] [Abstract][Full Text] [Related]
12. [The occurrence of glucuroconjugated metabolites of safrole in the urine of treated rats].
Levi P; Janiaud P; Delaforge M; Morizot JP; Maume BF; Padieu P
C R Seances Soc Biol Fil; 1977; 171(5):1034-40. PubMed ID: 146545
[TBL] [Abstract][Full Text] [Related]
13. The side-chain epoxidation and hydroxylation of the hepatocarcinogens safrole and estragole and some related compounds by rat and mouse liver microsomes.
Swanson AB; Miller EC; Miller JA
Biochim Biophys Acta; 1981 Apr; 673(4):504-16. PubMed ID: 7225430
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of labetalol by animals and man.
Martin LE; Hopkins R; Bland R
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
[TBL] [Abstract][Full Text] [Related]
15. Metabolic fate of the thrombolytic agent benzarone in man: comparison with the rat and dog.
Wood SG; John BA; Chasseaud LF; Bonn R; Grote H; Sandrock K; Darragh A; Lambe RF
Xenobiotica; 1987 Jul; 17(7):881-96. PubMed ID: 3660858
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
17. [Metabolic activation by adrenal tissue in rats of a liver carcinogen: safrole].
Doumas J; Maume BF
C R Seances Soc Biol Fil; 1977; 171(1):108-14. PubMed ID: 143305
[TBL] [Abstract][Full Text] [Related]
18. Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.
Maurer G; Schreier E; Delaborde S; Nufer R; Shukla AP
Eur J Drug Metab Pharmacokinet; 1983; 8(1):51-62. PubMed ID: 6861794
[TBL] [Abstract][Full Text] [Related]
19. Disposition of 2,3-dihydro-8-[2-hydroxy-3-[4-[1-oxo-3-(3,4, 5-trimethoxyphenyl)-2-propenyl]-1-piperazinyl]-propoxy]-1, 4-benzodioxin-5-carboxylic acid, isopentyl ester (TPBE) in rat and dog, and its hydrolysis in vitro in rat, dog and man.
Dow J; Benedetti MS
Xenobiotica; 1982 Oct; 12(10):633-43. PubMed ID: 7157833
[TBL] [Abstract][Full Text] [Related]
20. [Gastrointestinal absorption in the rat of anisole, trans-anethole, butylhydroxyanisole and safrole].
Fritsch P; de Saint Blanquat G; Derache R
Food Cosmet Toxicol; 1975 Jun; 13(3):359-63. PubMed ID: 1158324
[No Abstract] [Full Text] [Related]
[Next] [New Search]
